Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.
Camelliti S, Le Noci V, Bianchi F, Moscheni C, Arnaboldi F, Gagliano N, Balsari A, Garassino MC, Tagliabue E, Sfondrini L, Sommariva M.
Camelliti S, et al. Among authors: le noci v.
J Exp Clin Cancer Res. 2020 Nov 9;39(1):236. doi: 10.1186/s13046-020-01721-9.
J Exp Clin Cancer Res. 2020.
PMID: 33168050
Free PMC article.
Review.